Table 2.
Relationships betweenBAXmRNA expression status and other clinicopathological variables
| |
|
Number of patients (%) |
|
|
|
Variable |
Total |
BAX-negativea |
BAX-positivea |
Pvalue |
|
Cases |
88 |
35 (39.8) |
53 (60.2) |
|
|
Gender |
|
|
|
|
| Male |
51 |
19 (37.3) |
32 (62.7) |
0.66b |
| Female |
37 |
16 (43.2) |
21 (56.8) |
|
|
Age (years) |
|
|
|
|
| ≤ 30 |
25 |
6 (24.0) |
19 (76.0) |
0.09b |
| > 30 |
63 |
29 (46.0) |
34 (54.0) |
|
|
Tumor histology |
|
|
|
|
| Undifferentiated |
46 |
16 (34.8) |
30 (65.2) |
0.39b |
| Non-keratinizing |
42 |
19 (45.2) |
23 (54.8) |
|
|
Tumor extent |
|
|
|
|
| T1 / T2 |
33 |
7 (21.2) |
26 (78.8) |
0.014c |
| T3 |
19 |
8 (42.1) |
11 (57.9) |
|
| T4 |
36 |
20 (55.6) |
16 (44.4) |
|
|
Regional lymph node status |
|
|
|
|
| N0 |
14 |
7 (50.0) |
7 (50.0) |
0.024c |
| N1 |
14 |
1 (7.1) |
13 (92.9) |
|
| N2 |
28 |
10 (35.7) |
18 (64.3) |
|
| N3 |
32 |
17 (53.1) |
15 (46.9) |
|
|
Distant metastasis |
|
|
|
|
| M0 |
51 |
19 (31.1) |
42 (68.9) |
0.018b |
| M1 | 27 | 16 (59.3) | 11 (40.7) | |
aCutoff point: 0.43 a.u., equal to the 40th percentile.
bCalculated by chi-square (Χ2) test.
cCalculated by Fisher’s exact test.